menu
    • menu
    [{"orgOrder":0,"company":"On Target Laboratories","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Pafolacianine","moa":"Folate-alpha receptor||FOLR","graph1":"Oncology","graph2":"Phase III","graph3":"On Target Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"On Target Laboratories \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"On Target Laboratories \/ Syneos Health"},{"orgOrder":0,"company":"On Target Laboratories","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Pafolacianine","moa":"Folate-alpha receptor||FOLR","graph1":"Oncology","graph2":"Phase III","graph3":"On Target Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"On Target Laboratories \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"On Target Laboratories \/ Syneos Health"},{"orgOrder":0,"company":"On Target Laboratories","sponsor":"Clinipace Worldwide","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Pafolacianine","moa":"Folate-alpha receptor||FOLR","graph1":"Oncology","graph2":"Phase III","graph3":"On Target Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"On Target Laboratories \/ Clinipace Worldwide","highestDevelopmentStatusID":"10","companyTruncated":"On Target Laboratories \/ Clinipace Worldwide"},{"orgOrder":0,"company":"On Target Laboratories","sponsor":"Medelis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Pafolacianine","moa":"Folate-alpha receptor||FOLR","graph1":"Oncology","graph2":"Phase III","graph3":"On Target Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"On Target Laboratories \/ Medelis","highestDevelopmentStatusID":"10","companyTruncated":"On Target Laboratories \/ Medelis"},{"orgOrder":0,"company":"On Target Laboratories","sponsor":"On Target Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Pafolacianine","moa":"FOLR","graph1":"Oncology","graph2":"Phase I","graph3":"On Target Laboratories","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"On Target Laboratories \/ On Target Laboratories","highestDevelopmentStatusID":"6","companyTruncated":"On Target Laboratories \/ On Target Laboratories"},{"orgOrder":0,"company":"On Target Laboratories","sponsor":"On Target Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Pafolacianine","moa":"FOLR","graph1":"Oncology","graph2":"Phase I","graph3":"On Target Laboratories","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"On Target Laboratories \/ On Target Laboratories","highestDevelopmentStatusID":"6","companyTruncated":"On Target Laboratories \/ On Target Laboratories"},{"orgOrder":0,"company":"On Target Laboratories","sponsor":"On Target Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Pafolacianine","moa":"FOLR","graph1":"Oncology","graph2":"Phase I","graph3":"On Target Laboratories","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"On Target Laboratories \/ On Target Laboratories","highestDevelopmentStatusID":"6","companyTruncated":"On Target Laboratories \/ On Target Laboratories"},{"orgOrder":0,"company":"On Target Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Pafolacianine","moa":"FOLR","graph1":"Oncology","graph2":"Phase III","graph3":"On Target Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"On Target Laboratories \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"On Target Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"On Target Laboratories","sponsor":"John Waters","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Pafolacianine","moa":"FOLR","graph1":"Oncology","graph2":"Phase II","graph3":"On Target Laboratories","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"On Target Laboratories \/ John Waters","highestDevelopmentStatusID":"8","companyTruncated":"On Target Laboratories \/ John Waters"},{"orgOrder":0,"company":"On Target Laboratories","sponsor":"Cedars-Sinai","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Pafolacianine","moa":"FOLR","graph1":"Oncology","graph2":"Phase I","graph3":"On Target Laboratories","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"On Target Laboratories \/ On Target Laboratories","highestDevelopmentStatusID":"6","companyTruncated":"On Target Laboratories \/ On Target Laboratories"}]

    Find Clinical Drug Pipeline Developments & Deals by On Target Laboratories

    Menu

    On Target Laboratories

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            On Target Laboratories

                            U.S.A arrow
                            COMPAMED
                            Not Confirmed

                            On Target Laboratories

                            U.S.A arrow
                            COMPAMED
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pafolacianine

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Cedars-Sinai

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Intraoperative Imaging of Gastrointestinal Malignancies Using Pafolacianine (CYTALUXâ„¢)

                            Details : Pafolacianine is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Gastrointestinal Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 15, 2025

                            Lead Product(s) : Pafolacianine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Cedars-Sinai

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            On Target Laboratories

                            U.S.A arrow
                            COMPAMED
                            Not Confirmed

                            On Target Laboratories

                            U.S.A arrow
                            COMPAMED
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pafolacianine

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : John Waters

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            CYTALUX (Pafolacianine) Single-Dose Pilot Study For Intraoperative Cancer Tissue Detection

                            Details : Pafolacianine is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Esophageal Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 26, 2025

                            Lead Product(s) : Pafolacianine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : John Waters

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            On Target Laboratories

                            U.S.A arrow
                            COMPAMED
                            Not Confirmed

                            On Target Laboratories

                            U.S.A arrow
                            COMPAMED
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pafolacianine

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : University of California, Irvine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            PhI Pilot Study Pafolacianine Inject for Intraoperative Imaging on Outcomes of GI Cancer Peritoneal Carcinomat...

                            Details : Pafolacianine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Gastrointestinal Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 19, 2024

                            Lead Product(s) : Pafolacianine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : University of California, Irvine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            On Target Laboratories

                            U.S.A arrow
                            COMPAMED
                            Not Confirmed

                            On Target Laboratories

                            U.S.A arrow
                            COMPAMED
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pafolacianine

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Indiana University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            CYTALUXâ„¢for the Intraoperative Imaging of Prostate Cancer

                            Details : Pafolacianine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Prostatic Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 30, 2024

                            Lead Product(s) : Pafolacianine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Indiana University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            On Target Laboratories

                            U.S.A arrow
                            COMPAMED
                            Not Confirmed

                            On Target Laboratories

                            U.S.A arrow
                            COMPAMED
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pafolacianine

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Ann & Robert H Lurie Children's Hospital of Chicago

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Feasibility of Intraoperative Visualization With Cytalux in Children

                            Details : Pafolacianine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Osteosarcoma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 31, 2024

                            Lead Product(s) : Pafolacianine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Ann & Robert H Lurie Children's Hospital of Chicago

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            On Target Laboratories

                            U.S.A arrow
                            COMPAMED
                            Not Confirmed

                            On Target Laboratories

                            U.S.A arrow
                            COMPAMED
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pafolacianine

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            On Target Laboratories, Inc. Announces Presentation of the Results from the ELUCIDATE Phase 3 Trial for CYTALU...

                            Details : Cytalux (pafolacianine) is an FDA-approved optical imaging agent indicated in adult patients with ovarian cancer as an adjunct for intraoperative identification of malignant lesions.

                            Product Name : Cytalux

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 11, 2022

                            Lead Product(s) : Pafolacianine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            On Target Laboratories

                            U.S.A arrow
                            COMPAMED
                            Not Confirmed

                            On Target Laboratories

                            U.S.A arrow
                            COMPAMED
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pafolacianine

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Clinipace Worldwide

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ELUCIDATE: Enabling Lung Cancer Identification Using Folate Receptor Targeting

                            Details : OTL38 is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Lung Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 27, 2020

                            Lead Product(s) : Pafolacianine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Clinipace Worldwide

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            On Target Laboratories

                            U.S.A arrow
                            COMPAMED
                            Not Confirmed

                            On Target Laboratories

                            U.S.A arrow
                            COMPAMED
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pafolacianine

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Syneos Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            OTL38 for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer

                            Details : OTL38 is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Ovarian Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 08, 2017

                            Lead Product(s) : Pafolacianine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Syneos Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            On Target Laboratories

                            U.S.A arrow
                            COMPAMED
                            Not Confirmed

                            On Target Laboratories

                            U.S.A arrow
                            COMPAMED
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pafolacianine

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Medelis

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            OTL38 Injection for Intraoperative Imaging of Folate Receptor Positive Lung Nodules

                            Details : OTL38 is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Lung Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 19, 2016

                            Lead Product(s) : Pafolacianine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Medelis

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            On Target Laboratories

                            U.S.A arrow
                            COMPAMED
                            Not Confirmed

                            On Target Laboratories

                            U.S.A arrow
                            COMPAMED
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pafolacianine

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Syneos Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 2 Study of OTL38 for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian Cancer

                            Details : OTL38 is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Ovarian Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 16, 2014

                            Lead Product(s) : Pafolacianine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Syneos Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth